Drug-Drug Interaction


CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN/ULIPRISTAL

MECHANISM OF ACTION
Carbamazepine, phenobarbital, and phenytoin may induce the metabolism of ulipristal by CYP P-450-3A4.(1)

DISCUSSION
CYP P-450-3A4 inducers may decrease levels and effectiveness of ulipristal. Enzyme induction may take 2-3 weeks to wear off. Plasma levels of ulipristal may be reduced even if the CYP P-450-3A4 inducer was discontinued in the previous 2-3 weeks.(1)

CLINICAL EFFECTS
Concurrent use or use of carbamazepine, phenobarbital, or phenytoin within the previous 2-3 weeks may result in decreased levels and effectiveness of ulipristal.(1)

SEVERITY LEVEL
2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

PATIENT MANAGEMENT
The UK manufacturer of ulipristal states that concurrent use with CYP P-450-3A4 inducers such as carbamazepine, phenobarbital, or phenytoin is not recommended. Decreased effectiveness of ulipristal may occur even 2-3 weeks after discontinuation of these agents.(1)

PREDISPOSING FACTORS
None determined.

REFERENCE

  1. Ellaone (ulipristal acetate) UK summary of product characteristics. HRA .Ellaone (ulipristal acetate) UK summary of product characteristics. HRA Pharma UK Ltd May 15, 2009.